'Profound' Results With Ibrutinib Add-On in Mantle Cell Lymphoma

Results from the phase 3 SHINE trial show that adding ibrutinib to standard therapy delays progression by 50% in older patients with mantle cell lymphoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/975055?src=rss